The Global. An intense congress week in the field of oncology and hematology that augurs unique advances in the fight against diseases in these therapeutic areas. In total, three large events have been held that have focused the informative interest. The most important congress was the one organized by the American Society of Hematology (ASH), whose 58th annual meeting held in San Diego (California) has offered important advances. From the outset, the company AstraZeneca presented its strategic commitment to oncohematology. The company presented new clinical data on acalabrutinib, a potent and selective Bruton tyrosine kinase (BTK) inhibitor for the treatment of B-lymphocyte tumors. Specifically, it offered two studies of acalabrutinib monotherapy in patients with Richter syndrome and in patients with intolerance to ibrutinib, whose therapeutic mechanisms address unmet medical needs in patients with hematological cancers.

READ MORE